News
GLUE
17.00
+3.85%
0.63
Weekly Report: what happened at GLUE last week (0601-0605)?
Weekly Report · 1d ago
MONTE ROSA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/02 20:01
Monte Rosa Therapeutics CSO Sharon Townson disposes of common shares worth $119,220
PUBT · 06/01 20:07
Monte Rosa posts corporate deck spotlighting molecular glue degrader pipeline for immunology, inflammation and cancer targets
PUBT · 06/01 15:27
Weekly Report: what happened at GLUE last week (0525-0529)?
Weekly Report · 06/01 10:39
Monte Rosa COO Jennifer Champoux disposes of 2,175 shares for $43,500
PUBT · 05/28 23:11
Does Early MRT-2359 Data And Insider Selling Shift The Bull Case For Monte Rosa (GLUE)?
Simply Wall St · 05/28 06:05
Monte Rosa COO Jennifer Champoux sells 2,176 common shares worth $41,344
PUBT · 05/26 20:06
Weekly Report: what happened at GLUE last week (0518-0522)?
Weekly Report · 05/25 10:43
Monte Rosa director Anthony Manning disposes 10,000 shares worth $180,100
PUBT · 05/22 20:06
Monte Rosa to join TD Cowen Oncology Innovation Summit fireside chat
PUBT · 05/20 11:03
Weekly Report: what happened at GLUE last week (0511-0515)?
Weekly Report · 05/18 10:43
Monte Rosa Therapeutics Price Target Raised to $31.00/Share From $30.00 by JP Morgan
Dow Jones · 05/11 19:20
Monte Rosa Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 05/11 19:20
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $31
Benzinga · 05/11 19:10
Monte Rosa Therapeutics price target raised to $31 from $30 at JPMorgan
TipRanks · 05/11 13:44
Weekly Report: what happened at GLUE last week (0504-0508)?
Weekly Report · 05/11 10:40
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Strong Recent Share Price Momentum
Simply Wall St · 05/09 16:38
Analysts Conflicted on These Healthcare Names: Monte Rosa Therapeutics (GLUE) and Beam Therapeutics (BEAM)
TipRanks · 05/08 18:02
Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Monte Rosa Therapeutics (GLUE)
TipRanks · 05/07 19:20
More
Webull provides a variety of real-time GLUE stock news. You can receive the latest news about Monte Rosa Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About GLUE
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.